How we care Real change, with a team that actually sees you
Ready to take control of your biological age
dilution 1:200
2 GLP-1 0.25mg SD0.5mg SD1.0mg SD (Type 2 diabetes treatment agent Long-acting GLP-1 receptor agonist/semaglutide (genetical recombination) Ozempic subcutaneous injection 0.25mg SD, 0.5mg SD, 1.0mg SD New release information)
have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis), problems with digesting food, or severe stomach problems have a history of diabetic retinopathy have type 1 diabetes are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation) are pregnant or plan to become pregnant are breastfeeding or plan to breastfeed
Heterogeneous findings are organized by intervention/comparator, follow-up window, and key effect modifiers, including baseline obesity/insulin-resistance phenotype, concomitant metformin, and lifestyle co-interventions